Overview

  • Product name
    Anti-JAK3 (phospho Y785) antibody
    See all JAK3 primary antibodies
  • Description
    Rabbit polyclonal to JAK3 (phospho Y785)
  • Specificity
    ab61102 detects endogenous levels of JAK3 only when phosphorylated at tyrosine 785.
  • Tested applications
    Suitable for: IHC-P, ELISAmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthesized phosphopeptide derived from human JAK3 around the phosphorylation site of tyrosine 785 (S-D-YP-E-L).

  • Positive control
    • Human brain tissue

Properties

Applications

Our Abpromise guarantee covers the use of ab61102 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/50 - 1/100.
ELISA 1/5000.

Target

  • Function
    Tyrosine kinase of the non-receptor type, involved in the interleukin-2 and interleukin-4 signaling pathway. Phosphorylates STAT6, IRS1, IRS2 and PI3K.
  • Tissue specificity
    In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins.
  • Involvement in disease
    Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:600802]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
  • Sequence similarities
    Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
    Contains 1 FERM domain.
    Contains 1 protein kinase domain.
    Contains 1 SH2 domain.
  • Domain
    Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.
  • Post-translational
    modifications
    Tyrosine phosphorylated in response to IL-2 and IL-4.
  • Cellular localization
    Endomembrane system. Wholly intracellular, possibly membrane associated.
  • Information by UniProt
  • Database links
  • Alternative names
    • EC 2.7.10.2 antibody
    • JAK 3 antibody
    • JAK L antibody
    • JAK-3 antibody
    • Jak3 antibody
    • JAK3 HUMAN antibody
    • JAK3_HUMAN antibody
    • JAKL antibody
    • Janus kinase 3 (a protein tyrosine kinase, leukocyte) antibody
    • Janus kinase 3 antibody
    • Janus Kinase3 antibody
    • L JAK antibody
    • L-JAK antibody
    • Leukocyte janus kinase antibody
    • LJAK antibody
    • Protein tyrosine kinase leukocyte antibody
    • Tyrosine protein kinase JAK3 antibody
    • Tyrosine-protein kinase JAK3 antibody
    see all

Images

  • ab61102, at a 1/50 dilution, staining human JAK3 (phospho Y785) in brain, using Immunohistochemistry, Formalin/PFA fixed Paraffin embedded tissue, minus immunising peptide (left image) and plus immunising peptide (right image).

References

This product has been referenced in:
  • Datta R  et al. PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model. Allergy 66:853-61 (2011). WB ; Mouse . Read more (PubMed: 21276008) »

See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab61102.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up